New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
07:31 EDTFOLDAmicus Theraputics weakness a buying opportunity, says JPMorgan
JPMorgan views the pullback in shares of Amicus Theraputics on the company's Phase 3 trial miss as a buying opportunity. The firm says migalastat is active in Fabry and safe, and reiterates an Overweight rating on the stock, despite lowering its price target for shares to $5 from $9.
News For FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 15, 2015
06:09 EDTFOLDAmicus Therapeutics promotes Bradley Campbell to President and COO
Subscribe for More Information
January 12, 2015
07:49 EDTFOLDAmicus Therapeutics sees current cash to fund operations into 2017
Amicus Therapeutics provided its full-year 2015 strategic outlook and financial guidance. The company sees its FY15 net cash spend expected to range between $73M-$83M. Current cash of $169.1M at December 31, 2014 is projected to fund operating plan into 2017. Amicus said migalastat monotherapy FDA interaction is planned in 1Q15 and an MAA submission is on track for mid-2015 to seek marketing approval for Fabry patients with amenable mutations. Initiation of longer-term Phase 2 Fabry co-administration study is anticipated in 2015 in support of Fabry franchise strategy to develop migalastat in combination with ERT for Fabry patients with non-amenable mutations. Next-generation Pompe ERT is set to enter clinic in 2H15 and additional details on Pompe program are to be highlighted at 33rd Annual J.P. Morgan Healthcare Conference, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use